BioSpace News Archive

Policy

BIO Axes 30 Staff in Realignment as Congress Advances BIOSECURE Act

Following its recent about-face on the BIOSECURE Act, designed to combat China’s influence in the biopharma industry, lobbying group Biotechnology Innovation Organization in a realignment is laying off 30 employees.

May 21, 2024
·
2 min read
·
Tristan Manalac
Business

Lilly Inks Potential $1.1B Radiopharma Deal with Aktis Oncology

Eli Lilly is paying $60 million upfront to Aktis Oncology to discover and develop novel tumor-targeting radiopharmaceuticals, as radiopharma dealmaking continues to heat up in 2024.

May 21, 2024
·
2 min read
·
Kate Goodwin
Drug Development

GSK’s Long-Acting Asthma Drug Hits Primary Endpoint in Phase III Trials

Participants experienced fewer asthma attacks when receiving the antibody every six months, GSK said Tuesday, positioning the company to file for approval of the potential blockbuster.

May 21, 2024
·
2 min read
·
Nick Paul Taylor
Opinion: Annexon Tackles Guillain-Barre, Other Inflammatory Diseases with Novel Antibody

With Phase III trial results looming in the second quarter of 2024, Annexon Biosciences aims to transform treatment for Guillain-Barre syndrome with its investigational antibody, ANX005. The candidate is also being trialed in Huntington disease and ALS.

May 21, 2024
·
3 min read
·
Jia Jie Chen
Drug Development

Precision Medicine and Novel Approaches on Cusp of Breaking Through in Psychiatry

Approaches and targets for depression and other mental health illnesses have remained stagnant for decades. With several readouts for novel therapies on the horizon, that could be changing.

May 21, 2024
·
5 min read
·
Kate Goodwin
Career Advice

Do You Need to Love Your Job to Be Happy at Your Job?

Odds are, you won’t love every job. Is that OK? And what should you do if you’re struggling to find happiness at work?

May 21, 2024
·
4 min read
·
Angela Gabriel
Drug Development

Sanofi, Regeneron Post Strong Phase III COPD Data for Dupixent as FDA Decision Looms

Late-stage results from the NOTUS trial showed Sanofi and Regeneron’s Dupixent lowered moderate to severe chronic obstructive pulmonary disease exacerbations by 34% and led to significantly better lung function.

May 21, 2024
·
2 min read
·
Tristan Manalac
Drug Development

AltruBio Raises $225M in Series B to Advance Ulcerative Colitis Candidate

Formerly known as AbGenomics Holding, AltruBio on Tuesday said it will use the funds to push its ulcerative colitis asset into a Phase IIb trial with an anticipated readout in 2026.

May 21, 2024
·
2 min read
·
Tyler Patchen
Moderna Among Companies Partnering With OpenAI to Boost AI Efforts

Through its work with OpenAI, Moderna has given employees access to AI tools that aid their daily work and positioned itself for growth.

May 21, 2024
·
5 min read
·
Angela Gabriel
Bayer’s New Strategy, Novo Vs. Lilly and Psychedelics

Mass layoffs represent a step for Bayer toward reducing managerial layers, while clinical results released in the last week could influence the parallel races between Novo Nordisk and Eli Lilly in the GLP-1 and insulin spaces.

May 21, 2024
·
1 min read
·
Greg Slabodkin, Heather McKenzie, Tyler Patchen